Browsing Tag
Biogen
24 posts
Stoke Therapeutics has enrolled its pivotal Dravet trial, but what must the August 3 call prove?
Stoke Therapeutics will discuss its second-quarter performance on August 3 after completing enrollment in the pivotal EMPEROR trial. Investors will be looking beyond quarterly revenue to assess spending, regulatory execution and preparations for a possible zorevunersen launch.
Biogen stock (NASDAQ: BIIB) falls 8.2%: Can diranersen recover in Phase 3?
Biogen’s diranersen reduced tau and showed its strongest clinical result at the lowest dose, but the Phase 2 study missed its dose-response goal. With $BIIB down 8.2%, July 29 results and the Phase 3 design become the next tests.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Biogen is paying up to $1bn for preclinical optionality. What does RayThera really add?
Biogen's $1 billion RayThera deal expands its immunology pipeline and raises fresh capital allocation questions. Read what BIIB investors should watch next.
Biogen (BIIB) buys felzartamab rights in China from TJ Biopharma for up to $850m, completing global ownership
Biogen pays $100M upfront for felzartamab's China rights from TJ Biopharma, completing global ownership of the CD38 antibody with up to $850M at stake. Read the full analysis.
The inside story behind Samsung Bioepis’ European biosimilar takeover
Samsung Bioepis reclaims control of BYOOVIZ in Europe from Biogen, launching its own brand with a PFS version due in 2026. Read what this means for biosimilars.
Leqembi gains traction in China as commercial insurance innovative drug list expands access for Alzheimer’s patients
Leqembi gains commercial insurance status in China, opening doors for Alzheimer’s patients and transforming access. Find out what this means for BioArctic AB and Eisai.
Will Biogen’s $1bn bet on Vanqua Bio’s oral inflammation drug jumpstart its post-MS future?
Biogen’s $1.06B Vanqua Bio licensing deal signals a strategic shift toward immunology. Explore the roadmap behind this bold preclinical move.
Eisai’s etalanetug earns FDA Fast Track status, signaling new hope in Alzheimer’s therapy
Eisai’s etalanetug gets FDA Fast Track for Alzheimer’s, signaling a major shift toward tau-targeting therapies. Find out what this means for investors.